Live
- Call to inculcate habit of reading books
- 63% parents give milk to their kids to maintain intake of calcium
- Maoist Leader Manjula Surrenders in Warangal, Receives ₹20 Lakh Reward
- Kartika Purnima celebrations fervour marks Telugu States, devotees flock to shiva shrines
- YSRCP alleges meagre fund allocations for Super Six schemes
- Telangana CM Reviews Plans for First Anniversary of State Government
- Vijayawada: Kindness Day celebrated
- Rajamahendravaram: Students advised to set clear goals
- Digital locker facility now available at Namma Metro stations
- Swarna Vaijayanthi Mala presented to Tirumala god
Hetero gets Drug Controller General of India nod for fixed dose HIV drug
Hetero, one of India’s leading generic pharmaceutical companies and one of the world’s largest producer of anti-retroviral drugs, has launched its first-ever generic fixed-dose drug Darunavir + Ritonavir.’
Hyderabad: Hetero, one of India’s leading generic pharmaceutical companies and one of the world’s largest producer of anti-retroviral drugs, has launched its first-ever generic fixed-dose drug Darunavir + Ritonavir.’ Hetero has received the approval from Drug Controller General of India (DCGI) to launch the fixed-dose combination (FDC) drug ‘Darunavir + Ritonavir’ in India.
The product will be marketed and distributed under the brand ‘DANAVIR-R’ by Hetero Healthcare Ltd. It’s available in three strengths - 800/100mg, 600/100mg and 400/50mg, according to a release. Dr BPS Reddy, CMD, Hetero Group, said: “Hetero is proud of extending its latest offering ‘Darunavir+Ritonavir’ FDC in three strengths for HIV/AIDS patients.
We will continue to invest in R&D capabilities and will develop such world-class anti-retroviral drug combinations in future.” The FDC drug ‘Darunavir +Ritonavir’ is an anti-retroviral medication indicated for the treatment of HIV-1.
